Clinical Trials on Treatment Outcomes in Finland

Total 54 results

Niuvanniemi Hospital

Active, not recruiting

Navigated αTMS in Treatment-resistant Schizophrenia (nTMS_NS)

Schizophrenia | Schizoaffective Disorder

Finland
Tampere University

Completed

Effectiveness of Narrative Exposure Therapy Among Refugee Children and Adolescents

Treatment as Usual | Narrative Exposure Therapy

Finland
Women and Infants Hospital of Rhode Island

Completed

NICU Parent Education Program (NICU PEP)

Premature Infant | Language Development | Neurodevelopmental Outcomes

United States
Turku University Hospital

Unknown

Serum Biomarker HE4 During IVF Treatment (FHE4)

IVF Treatment | Human Epididymal Secretory Protein E4

Finland
Takeda

Completed

Vortioxetine (Lu AA21004) 10 and 20 mg for Treatment of Major Depressive Disorder With Sexual Dysfunction

Treatment Outcome

United States, Canada
University of California, San Francisco
Kenya Medical Research Institute; Organic Health Response; Microclinic International

Completed

Healthy Networks Water Treatment Study (HNWT)

Household Water Treatment | Waterborne Illness

Kenya
Turku University Hospital
University of Turku; Academy of Finland; Foundation for Paediatric Research,... and other collaborators

Completed

A Prenatal Mentalization-focused 4D Ultrasound and a Pregnancy Diary Intervention for Substance-abusing Women

Substance-Related Disorders | Depression | Anxiety | Pregnancy, High Risk | Parenting | Maternal-Fetal Relations | Prenatal Care | Fetal Exposure During Pregnancy | Perinatal Outcome

Finland
Joint Authority for Päijät-Häme Social and Health...
Kanta-Häme Central Hospital

Recruiting

Laparoscopic Approach for Emergency Colon Resection

Laparoscopic Surgery | Emergencies | Colorectal Cancer | Colorectal Disorders | Complication of Surgical Procedure | Long-term Effects of Cancer Treatment

Finland
Butler Hospital
National Institute of General Medical Sciences (NIGMS)

Recruiting

Exercise to Augment TMS in Those With Treatment Resistant Depression

Treatment Resistant Depression

United States
Orthosensor, Inc.

Completed

Limited Market Release - MotionSense Clinical Use Evaluation (FS5)

Patient Engagement | Knee Arthroplasty | Patient-Reported Outcome Measures (PROMs)

United States
Massachusetts General Hospital
National Institute of Mental Health (NIMH); Temple University; Butler Hospital; University of Kansas and other collaborators

Terminated

Proof-of-Concept Trial of CERC-501 Augmentation of Antidepressant Therapy in Treatment-Resistant Depression (RAPID KOR)

Treatment Resistant Depression

United States
MedtronicNeuro

Completed

Reclaim Deep Brain Stimulation Clinical Study for Treatment-Resistant Depression

Depression

United States
Rhode Island Hospital

Completed

A Pilot Gaming Adherence Program for Youth Living With HIV

Adherence to HIV Treatment and Medication

United States
Northwell Health
Staten Island University Hospital

Completed

Fiber Intake in an End Stage Renal Disease (ESRD) Population Followed Over 2 Years

Lipid Profile | Cardiovascular Outcome | Kalemia Control

United States
Rhode Island Hospital

Recruiting

Family Navigator Intervention

Treatment as Usual | Family Navigator

United States
Lund University
Charite University, Berlin, Germany; University of Helsinki; Skane University... and other collaborators

Recruiting

Early Neuroprognostication After OHCA

Brain Injuries | Biomarkers | Cardiac Arrest | EEG | CT | Neurological Outcome

Sweden, Germany, Finland
Janssen Research & Development, LLC

Completed

A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression (SUSTAIN-2)

Treatment-resistant Depression

United States, Australia, France, United Kingdom, Belgium, Germany, Taiwan, Spain, Argentina, Mexico, Poland, Bulgaria, Malaysia, South Africa, Turkey, Finland, Korea, Republic of, Brazil, Austria, Sweden, Lithuania
Cyberonics, Inc.

Completed

Study Comparing Outcomes for Patients With Treatment Resistant Depression Who Receive VNS Therapy at Different Doses

Depression

United States
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression (TRANSFORM-1)

Treatment-resistant Depression

United States, France, Belgium, Mexico, Canada, Brazil, Estonia, Hungary, Slovakia
Rhode Island Hospital
National Institute on Drug Abuse (NIDA)

Completed

Digital Health Intervention to Support Opioid Use Disorder Treatment (iENDURE)

Opioid Use Disorder | Treatment Adherence

United States
LivaNova

Active, not recruiting

The RECOVER sUb-study, Which Leverages quaNtitative and Credible Research tOols From Verily, Will providE Assessment measuRes for Depressive Episodes (UNCOVER)

Treatment Resistant Depression

United States
COMPASS Pathways

Recruiting

Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD

Treatment Resistant Depression

United States, Spain, Ireland, France, United Kingdom, Canada
LivaNova

Recruiting

A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression (RECOVER)

Treatment Resistant Depression

United States
Merck Sharp & Dohme LLC

Terminated

Efficacy and Safety of MK-1942 When Added to Stable Antidepressant Therapy in Participants With Treatment-Resistant Depression (TRD) (MK-1942-006)

Treatment Resistant Depression

United States
Axsome Therapeutics, Inc.

Completed

Open-Label Safety Study of AXS-05 in Subjects With TRD (EVOLVE)

Major Depressive Disorder | Treatment Resistant Depression

United States
Axsome Therapeutics, Inc.

Completed

Mechanistic Evaluation of Response in TRD (MERIT) (MERIT)

Major Depressive Disorder | Treatment Resistant Depression

United States
Lifespan
National Institute on Drug Abuse (NIDA)

Recruiting

Injectable Extended-Release Buprenorphine (XR-B) in a Correctional Setting: Qualitative Interviews

Opioid Use Disorder | Treatment Adherence and Compliance | Criminal Justice

United States
Eli Lilly and Company

Completed

The Study of Olanzapine Plus Fluoxetine in Combination for Treatment of Treatment Resistant Depression

Major Depressive Disorder

United States, Canada
Brigham and Women's Hospital
Johns Hopkins University; Massachusetts General Hospital; Washington University... and other collaborators

Completed

The Provider Awareness and Cultural Dexterity Toolkit for Surgeons Trial (PACTS)

Resident Knowledge and Attitudes Regarding Cross-cultural Care | Interpersonal and Communication Skills in Patient-clinician Encounters | Patient-reported Satisfaction With Resident Physicians Involved in Their Care | Patients' Clinical Health Outcomes After Surgery

United States
Eli Lilly and Company

Completed

A Study in Relapse Prevention of Treatment-Resistant Depression

Treatment Resistant Depression

United States, Argentina, Russian Federation, South Africa, India, Turkey, Puerto Rico, Mexico
Axsome Therapeutics, Inc.

Completed

Open-Label Safety Study of AXS-05 in Subjects With Depression

Depression | Major Depressive Disorder | Treatment Resistant Depression

United States
Cyberonics, Inc.

Completed

Treatment-Resistant Depression Registry

Major Depressive Disorder

United States
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression (TRANSFORM-3)

Depressive Disorder, Treatment-Resistant

United States, France, Belgium, Spain, Poland, Bulgaria, South Africa, Finland, Brazil, Sweden, United Kingdom, Lithuania
Janssen Research & Development, LLC

Completed

A Study of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants With Treatment-resistant Depression

Depressive Disorder, Treatment-Resistant

United States
Janssen Research & Development, LLC

Completed

A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression (SUSTAIN-3)

Depressive Disorder, Treatment-Resistant

United States, France, Poland, United Kingdom, Belgium, Germany, Taiwan, Spain, Argentina, Mexico, Bulgaria, Malaysia, South Africa, Turkey, Canada, Korea, Republic of, Brazil, Estonia, Hungary, Lithuania, Slovakia, Sweden, Czechia, A... and more
Avanir Pharmaceuticals

Completed

Efficacy, Safety, and Tolerability Study of AVP-786 as an Adjunctive Therapy in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment

Depressive Disorder, Treatment-Resistant

United States
ACADIA Pharmaceuticals Inc.

Terminated

Extension Study of Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment

Adjunctive Treatment of Major Depressive Disorder

United States, Serbia, Finland, Poland, Russian Federation, Slovakia, South Africa, Ukraine, United Kingdom
Southwest Oncology Group
National Cancer Institute (NCI); Cancer and Leukemia Group B

Completed

SWOG-9208 Quality of Life and Health Status in Patients With Stage I or Stage II Hodgkin's Disease

Lymphoma | Psychosocial Effects of Cancer and Its Treatment

United States
ACADIA Pharmaceuticals Inc.

Completed

Study to Evaluate the Efficacy and Safety of Adjunctive Pimavanserin in Major Depressive Disorder (CLARITY)

Adjunctive Treatment of Major Depressive Disorder

United States
ACADIA Pharmaceuticals Inc.

Completed

Adjunctive Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment

Adjunctive Treatment of Major Depressive Disorder

United States, Serbia, Finland, Poland, Russian Federation, Ukraine, United Kingdom, Slovakia, South Africa
Clexio Biosciences Ltd.

Completed

A Study of CLE-100 (Oral Esketamine) in Addition to Standard Antidepressant Drug for Major Depressive Disorder - CLEO Study

Adjunctive Treatment of Major Depressive Disorder

United States, Puerto Rico
GlaxoSmithKline

Completed

ARTS - AVODART After Radical Therapy For Prostate Cancer Study (ARTS)

Neoplasms, Prostate | Prostate Cancer After a Radical Treatment

Spain, Estonia, Netherlands, United Kingdom, Germany, Finland, France, Russian Federation, Sweden
Axsome Therapeutics, Inc.

Completed

A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Treatment Resistant Major Depressive Disorder (STRIDE-1)

Treatment Resistant Major Depressive Disorder

United States
Pfizer

Completed

Dose Ranging Study of Rimegepant (BMS-927711) for the Acute Treatment of Migraine

Migraine | Acute Treatment of Migraine

United States
Amgen

Completed

A Study to Assess the Long-term Safety and Efficacy of Erenumab (AMG 334) in Chronic Migraine Prevention.

Treatment for Prevention of Chronic Migraine

United States, United Kingdom, Poland, Germany, Czechia, Sweden, Canada, Denmark, Finland, Norway
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Chemotherapy Decisions and Outcomes in Older Women With Newly Diagnosed Breast Cancer

Breast Cancer | Psychosocial Effects of Cancer and Its Treatment

United States
The George Washington University Biostatistics...
Eunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaborators

Completed

Antenatal Late Preterm Steroids (ALPS): A Randomized Placebo-Controlled Trial (ALPS)

Pregnancy | Preterm Birth | Respiratory Distress Syndrome | Pregnancy Outcomes

United States
Amgen

Completed

A Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Chronic Migraine Prevention

Treatment for Prevention of Chronic Migraine

United States, United Kingdom, Poland, Germany, Czechia, Sweden, Canada, Denmark, Finland, Norway
Brown University
Taiho Oncology, Inc.

Recruiting

TAS-116 Plus Palbociclib in Breast and Rb-null Cancer

Soft Tissue Sarcoma | Advanced Breast Cancer | SCLC | Bladder Cancer | Endometrial Cancer | Treatment-Refractory Solid Tumors | Retinoblastoma Deficiency

United States
Janssen Research & Development, LLC

Completed

A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression (SUSTAIN-1)

Depressive Disorder, Treatment-Resistant

United States, France, Poland, Belgium, Germany, Spain, Mexico, Turkey, Canada, Brazil, Estonia, Hungary, Slovakia, Sweden, Czechia

Clinical Trials on Treatment Outcomes in Finland

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mozambique

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations